Compounded drugs vs. FDA-approved drugs
What FDA approval means, what compounding means, and why compounded drugs are not generic drugs.
6 sections · 3 FAQs · 4 sources
Read guide →Independent research • Source-backed profiles • No paid rankings
Topic pillar
Compounded medications
Plain-language guides to compounding, pharmacy disclosure, and the limits of FDA review.
Primary research topic: compounded peptides
Guides in this topic
Use these guides together: begin with the overview, follow the verification steps, and confirm time-sensitive regulatory information through the linked primary sources.
Peptide storage information: why the dispensing source matters
Storage instructions can vary by exact product, formulation, packaging, and pharmacy. This guide separates what is known, what is marketed, and what consumers can verify before choosing a provider.
4 sections · 4 FAQs · 2 sources
Read guide →503A versus 503B pharmacies: a consumer research guide
The terms 503A and 503B describe different federal compounding frameworks, not quality awards. This guide separates what is known, what is marketed, and what consumers can verify before choosing a provider.
4 sections · 4 FAQs · 2 sources
Read guide →Peptide purity and quality claims: what a certificate cannot prove
Sellers may publish purity percentages, certificates of analysis, or third-party testing badges. This guide separates what is known, what is marketed, and what consumers can verify before choosing a provider.
4 sections · 4 FAQs · 2 sources
Read guide →How to verify a compounding pharmacy
The pharmacy’s legal identity and current licenses should be independently checked. This guide separates what is known, what is marketed, and what consumers can verify before choosing a provider.
4 sections · 4 FAQs · 2 sources
Read guide →How to report a compounded peptide problem to FDA MedWatch
Patients and health professionals can voluntarily report serious adverse events, medication errors, and product-quality problems involving compounded drugs through FDA MedWatch. A useful report preserves the label, compounder, concentration, lot, dates, route, and a factual description without claiming causation.
6 sections · 6 FAQs · 4 sources
Read guide →How to read an FDA Form 483 for a compounding pharmacy
An FDA Form 483 records inspection observations that may constitute violations; it is not a final agency decision. Consumers should read it with the firm's response, later warning letters or closeout records, current registration, state-license information, recalls, and the inspection date.
7 sections · 6 FAQs · 4 sources
Read guide →How to check compounded drug recalls and match your product
A recall search must match more than a product name. Use the legal compounder, product, strength, dosage form, lot, distribution dates, and recall notice together, then contact the dispensing pharmacy or prescriber when a possible match exists.
7 sections · 6 FAQs · 4 sources
Read guide →503A Category 1, 2, and 3 bulk substances: what the lists mean
FDA’s 503A nomination categories are part of an interim enforcement policy while the agency evaluates bulk drug substances. They are not approval tiers, pharmacy ratings, or a substitute for the final 503A Bulks List.
6 sections · 6 FAQs · 4 sources
Read guide →Compounded GLP-1 “essentially a copy” rule: a 2026 guide
FDA’s April 2026 clarification explains when a compounded GLP-1 product may be treated as essentially a copy of a commercially available or approved drug. The analysis differs under 503A and 503B and cannot be reduced to whether a clinic adds an ingredient.
6 sections · 6 FAQs · 5 sources
Read guide →FDA Import Alert 66-80: how to research GLP-1 bulk ingredients
Import Alert 66-80 guides FDA staff on detention without physical examination of certain imported GLP-1 ingredients. Its Green List is not FDA approval or a safety certificate.
6 sections · 6 FAQs · 5 sources
Read guide →Compounded GLP-1 adverse-event reports: how to interpret FDA’s 2026 counts
FDA’s May 31, 2026 counts are safety-surveillance signals, not incidence rates or proof that a compounded product caused each event. Underreporting and data gaps also matter.
6 sections · 6 FAQs · 5 sources
Read guide →How to read a compounded peptide label: strength, lot, and beyond-use date
A label cannot prove that a compounded drug is FDA-approved or appropriate, but it should give you the identifiers needed to verify the product, avoid strength confusion, match recalls, and report problems.
6 sections · 6 FAQs · 5 sources
Read guide →Semaglutide sodium and acetate: why FDA distinguishes salt forms from the base
FDA says semaglutide sodium and semaglutide acetate are different active ingredients from the semaglutide base used in approved drugs and that it is not aware of a lawful basis for using those salts in compounding.
6 sections · 6 FAQs · 5 sources
Read guide →Are NAD+ injections FDA-approved? Compounding status, safety alerts, and provider checks
NAD+ is a peptide-adjacent longevity service advertised by many peptide clinics, but it is not a peptide and compounded NAD+ injections are not FDA-approved products. Current federal pathways and ingredient quality require separate checks.
6 sections · 6 FAQs · 5 sources
Read guide →FDA drug shortage list and peptide compounding: how to verify a clinic’s claim
A nationwide FDA shortage can change specific federal copying and bulk-substance conditions, but it does not approve a compounded drug, guarantee availability, or suspend the rest of sections 503A and 503B.
6 sections · 6 FAQs · 5 sources
Read guide →FDA’s 503B GLP-1 bulks-list proposal: what happens after the July 2026 comment period
The comment period has closed, but FDA has not made its final bulks-list determination; consumers should separate the proposal from shortage rules, 503A compounding, and product approval.
6 sections · 6 FAQs · 5 sources
Read guide →USP <797> and compounded peptide injections: what consumers can verify
USP <797> sets minimum standards for compounded sterile preparations, but citing the chapter does not make a peptide FDA-approved or prove that a particular pharmacy, batch, or use is safe.
6 sections · 6 FAQs · 5 sources
Read guide →Fake compounded GLP-1 drugs: how to check the label and pharmacy
FDA says some products labeled as compounded semaglutide or tirzepatide name pharmacies that do not exist or did not make the product; this guide explains a verification-first response.
6 sections · 6 FAQs · 4 sources
Read guide →Compounded semaglutide dosing errors: units, milligrams, and concentration checks
Variable concentrations and unclear conversions can turn the same syringe marking into different drug amounts; verify the prescription, label, and device with the pharmacist rather than calculating from another vial.
6 sections · 6 FAQs · 4 sources
Read guide →Compounded semaglutide with B12: evidence, FDA rules, and marketing claims
Adding cyanocobalamin does not make compounded semaglutide FDA-approved, prove better results, or automatically avoid federal restrictions on essentially copies.
6 sections · 6 FAQs · 4 sources
Read guide →Peptide medication arrived warm? How to research a shipping temperature excursion
A warm package does not have one universal answer: preserve the evidence, identify the exact product, and obtain product-specific instructions before deciding what to do.
6 sections · 6 FAQs · 5 sources
Read guide →